Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial
Frédéric Houssiau,David D'Cruz,Shirish Sangle,Philippe Remy,Carlos Vasconcelos,Radmila Petrovic,Christoph Fiehn,Enrique de Ramón Garrido,Inge-Magrethe Gilboe,Maria G Tektonidou,Daniel Engelbert Blockmans,Isabelle Ravelingien,Véronique Le Guern,Geneviève Depresseux,Loïc Guillevin,Ricard Cervera +15 more
Reads0
Chats0
TLDR
Fewer renal flares were observed in patients receiving MMF but the difference did not reach statistical significance and over a 3-year period, 24 h proteinuria, serum creatinine, serum albumin, serum C3, haemoglobin and global disease activity scores improved similarly in both groups.Abstract:
Long-term immunosuppressive treatment does not efficiently prevent relapses of lupus nephritis (LN). This investigator-initiated randomised trial tested whether mycophenolate mofetil (MMF) was superior to azathioprine (AZA) as maintenance treatment.read more
Citations
More filters
Journal ArticleDOI
American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis
Bevra H. Hahn,Maureen McMahon,Alan H. Wilkinson,W. Dean Wallace,David I. Daikh,John FitzGerald,George Karpouzas,Joan T. Merrill,Daniel J. Wallace,Jinoos Yazdany,Rosalind Ramsey-Goldman,Karandeep Singh,Mazdak A. Khalighi,Soo I. Choi,Maneesh Gogia,Suzanne Kafaja,Mohammad Kamgar,Christine Lau,William J. Martin,Sefali Parikh,Justin Peng,Anjay Rastogi,Weiling Chen,Jennifer M. Grossman +23 more
TL;DR: The management strategies discussed here apply to lupus nephritis in adults, particularly to those receiving care in the United States of America, and include interventions that were available in theUnited States as of April 2011.
Journal ArticleDOI
2019 update of the EULAR recommendations for the management of systemic lupus erythematosus
Antonis Fanouriakis,Myrto Kostopoulou,Alessia Alunno,Martin Aringer,Ingeborg M. Bajema,John Boletis,Ricard Cervera,Andrea Doria,Caroline Gordon,Marcello Govoni,Frédéric Houssiau,David Jayne,Marios Kouloumas,Annegret Kuhn,Janni Lisander Larsen,Kirsten Lerstrøm,Gabriella Moroni,Marta Mosca,Matthias Schneider,Josef S Smolen,Elisabet Svenungsson,Vladimir Tesar,Angela Tincani,Anne Troldborg,Ronald F van Vollenhoven,Jörg Wenzel,George Bertsias,Dimitrios T. Boumpas +27 more
TL;DR: The updated recommendations provide physicians and patients with updated consensus guidance on the management of SLE, combining evidence-base and expert-opinion, based on emerging new evidence.
Journal ArticleDOI
Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis
George Bertsias,Maria G Tektonidou,Zahir Amoura,Martin Aringer,Ingeborg M. Bajema,Jo H. M. Berden,John Boletis,Ricard Cervera,Thomas Dörner,Andrea Doria,Franco Ferrario,Jürgen Floege,Frédéric Houssiau,John P. A. Ioannidis,David A. Isenberg,Cees G. M. Kallenberg,Liz Lightstone,Stephen D. Marks,Alberto Martini,G. Moroni,Irmgard Neumann,Manuel Praga,Matthias Schneider,Argyre Starra,Vladimir Tesar,Carlos Vasconcelos,Ronald F van Vollenhoven,Helena Zakharova,Marion Haubitz,Caroline Gordon,David Jayne,Dimitrios T. Boumpas +31 more
TL;DR: Recommendations for the management of lupus nephritis were developed using an evidence-based approach followed by expert consensus and there is no evidence to suggest that management of LN should differ in children versus adults.
KDIGO Clinical Practice Guideline for Glomerulonephritis
TL;DR: This chapter discusses general principles in the management of glomerular disease, as well as methods for guideline development and examples of successful implementation of these principles.
Journal ArticleDOI
Systemic lupus erythematosus.
Arvind Kaul,Caroline Gordon,Mary K. Crow,Zahi Touma,Murray B. Urowitz,Ronald F van Vollenhoven,Guillermo Ruiz-Irastorza,Graham R. V. Hughes +7 more
TL;DR: The 10-year mortality has improved and toxic adverse effects of older medications such as cyclophosphamide and glucocorticoids have been partially offset by newer drugs such as mycophenolate mofetil and glucose-sparing regimes.
References
More filters
Journal ArticleDOI
The 1982 revised criteria for the classification of systemic lupus erythematosus
Eng M. Tan,Alan S. Cohen,James F. Fries,Alfonse T. Masi,Dennis J. McShane,Naomi F. Rothfield,Jane G. Schaller,Norman Talal,Robert Winchester +8 more
TL;DR: The 1971 preliminary criteria for the classification of systemic lupus erythematosus (SLE) were revised and updated to incorporate new immunologic knowledge and improve disease classification and showed gains in sensitivity and specificity.
Journal ArticleDOI
Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus.
TL;DR: In 1992, Piette and colleagues suggested that the ACR revised criteria be reevaluated in light of the above discoveries, and the presence and clinical associations or antiphospholipid antibodies in patients with SLE was suggested.
Journal ArticleDOI
Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE.
TL;DR: The development of the SLEDAI is described, a validated model of experienced clinicians' global assessments of disease activity in lupus, which represents the consensus of a group of experts in the field of l upus research.
Journal ArticleDOI
Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus
Mary J. Roman,Beth-Ann Shanker,Adrienne Davis,Michael D. Lockshin,Lisa R. Sammaritano,Ronit Simantov,Mary K. Crow,Joseph E. Schwartz,Stephen A. Paget,Richard B. Devereux,Jane E. Salmon +10 more
TL;DR: The clinical profile of patients with lupus and atherosclerosis suggests a role for disease-related factors in atherogenesis and underscores the need for trials of more focused and effective antiinflammatory therapy.
Journal ArticleDOI
Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients
Ricard Cervera,Munther A. Khamashta,Josep Font,Gian Domenico Sebastiani,Antonio Gil,Lavilla P,Juan Carlos Mejía,A. Olcay Aydintug,Hanna Chwalinska-Sadowska,Enrique de Ramón,Antonio Fernández-Nebro,Mauro Galeazzi,Merete Valen,Alessandro Mathieu,Frédéric Houssiau,Natividad Caro,Paula Alba,Manuel Ramos-Casals,Miguel Ingelmo,Graham R. V. Hughes +19 more
TL;DR: In this paper, the authors assessed the frequency and characteristics of the main causes of morbidity and mortality in systemic lupus erythematosus (SLE) during a 10-year period and compared the frequency of early manifestations with those that appeared later in the evolution of the disease.
Related Papers (5)
Mycophenolate Mofetil versus Cyclophosphamide for Induction Treatment of Lupus Nephritis
Gerald B. Appel,Gabriel Contreras,Mary Anne Dooley,Ellen M. Ginzler,David A. Isenberg,David Jayne,Lei Shi Li,Eduardo Mysler,Jorge Sánchez-Guerrero,Neil Solomons,David Wofsy,Carlos Abud,Sharon G. Adler,Graciela S. Alarcón,Elisa N. Albuquerque,Fernando Almeida,Alejandro Alvarellos,Gerald B. Appel,Hilario Avila,Cornelia Blume,Ioannis Boletis,Alain Bonnardeaux,Alan Braun,Jill P. Buyon,Ricard Cervera,Nan Chen,Shun-Le Chen,António Gomes Da Costa,Razeen Davids,David D'Cruz,Enrique de Ramón,Atul Deodhar,Andrea Doria,Bertrand Dussol,Paul Emery,Justus Fiechtner,Jürgen Floege,Hilda Fragoso-Loyo,Richard Furie,Rozina Ghazalli,Cybele Ghossein,Gary S. Gilkeson,EM Ginzler,Caroline Gordon,Jennifer M. Grossman,Jieruo Gu,Loïc Guillevin,Pierre Yves Hatron,Gisela Herrera,Falk Hiepe,Frédéric Houssiau,Osvaldo Hübscher,Claudia Hura,Joshua Kaplan,Gianna Mastroianni Kirsztajn,Emese Kiss,Ghazali Ahmad Kutty,Maurice Laville,Maria Lazaro,Oliver Lenz,Leishi Li,Liz Lightstone,Sam Lim,Michel Malaise,Susan Manzi,Juan Carlos Marcos,Olivier Meyer,Pablo Monge,Saraladev Naicker,Nathaniel Neal,Michael Neuwelt,Kathy Nicholls,Nancy J. Olsen,José Ordi-Ros,Barbara E. Ostrov,Manuel Pestana,Michelle Petri,G. Pokorny,Jacques Pourrat,Jiaqi Qian,Jai Radhakrishnan,Brad H. Rovin,Julio Sanchez Roman,Joseph C. Shanahan,William Shergy,Fotini Skopouli,Alberto Spindler,Christopher Striebich,Robert Sundel,Charles R. Swanepoel,Yen Tan Si,Guillermo Tate,Vladimír Tesaŕ,Mohamed Tikly,Haiyan Wang,Rosnawati Yahya,Xueqing Yu,Fengchun Zhang,Diana Zoruba +98 more
Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide.
Frédéric Houssiau,Carlos Vasconcelos,David D'Cruz,Gian Domenico Sebastiani,Enrique de Ramón Garrido,Maria Giovanna Danieli,Daniel Abramovicz,Daniel Engelbert Blockmans,Alessandro Mathieu,Haner Direskeneli,Mauro Galeazzi,Ahmet Gül,Yair Levy,Peter Petera,Rajko Popovic,Radmila Petrovic,Renato Alberto Sinico,Roberto Cattaneo,Josep Font,Geneviève Depresseux,Jean-Pierre Cosyns,Ricard Cervera +21 more
American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis
Bevra H. Hahn,Maureen McMahon,Alan H. Wilkinson,W. Dean Wallace,David I. Daikh,John FitzGerald,George Karpouzas,Joan T. Merrill,Daniel J. Wallace,Jinoos Yazdany,Rosalind Ramsey-Goldman,Karandeep Singh,Mazdak A. Khalighi,Soo I. Choi,Maneesh Gogia,Suzanne Kafaja,Mohammad Kamgar,Christine Lau,William J. Martin,Sefali Parikh,Justin Peng,Anjay Rastogi,Weiling Chen,Jennifer M. Grossman +23 more